Saturn V Capital Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Saturn V Capital Management LP reported 24 stock positions worth $255.4 million. Its top holding was Disc Medicine (IRON) at 12.6% of the portfolio, followed by Ascendis Pharma A/S (ASND, 10.7%) and Moonlake Immunotherapeutics (MLTX, 7.3%). Compared with Q3 2024, it opened 5 new positions, sold out of 6, added to 10 and reduced 8. The biggest buy was a new position in Xenon Pharmaceuticals (XENE) and the biggest sale an exit from Phathom Pharmaceuticals (PHAT).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $255.4M (Q4 2024)
- SEC Filing
- 0001964437-25-000003 ↗ filed Feb 14, 2025
Holdings Value
Holdings 24 stocks · $255.4M
| IRON Disc Medicine Inc. | 12.65% | 509,406 | $32.3M | Reduce -0.3% |
| ASND Ascendis Pharma A/S | 10.73% | 198,977 | $27.4M | Reduce -0.7% |
| MLTX Moonlake Immunotherapeutics | 7.34% | 346,111 | $18.7M | Add +15.8% |
| CGON CG Oncology Inc. | 6.66% | 593,262 | $17.0M | Add +14.1% |
| PCVX Vaxcyte Inc. | 6.55% | 204,285 | $16.7M | Reduce -0.3% |
| CYTK Cytokinetics Inc. | 6.42% | 348,364 | $16.4M | Add +5.2% |
| CRGX Cargo Therapeutics Inc. | 5.69% | 1,007,677 | $14.5M | Add +0.5% |
| CELC Celcuity Inc. | 5.45% | 1,063,783 | $13.9M | Add +12.4% |
| SNDX Syndax Pharmaceuticals Inc. | 5.12% | 988,528 | $13.1M | Add +96.9% |
| XENE Xenon Pharmaceuticals Inc. | 4.95% | 322,470 | $12.6M | New |
| ARGX Argenx SE - ADR | 4.76% | 19,754 | $12.1M | Reduce -10.7% |
| COGT Cogent Biosciences Inc. | 4.58% | 1,498,425 | $11.7M | Reduce -12.5% |
| MRUS Merus NV | 3.86% | 234,637 | $9.9M | Add +78.8% |
| CTNM Contineum Therapeutics Inc. Class A | 3.29% | 573,022 | $8.4M | Add +641.3% |
| ABVX Abivax SA-ADR | 1.87% | 653,071 | $4.8M | Add +0.8% |
| KALV Kalvista Pharmaceuticals Inc. | 1.85% | 556,489 | $4.7M | No change |
| INZY Inozyme Pharma Inc. | 1.49% | 1,374,582 | $3.8M | Add +0.4% |
| IRWD Ironwood Pharmaceuticals Inc. | 1.41% | 814,533 | $3.6M | Reduce -27.3% |
| AMLX Amylyx Pharmaceuticals Inc. | 1.32% | 889,073 | $3.4M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 1.18% | 59,125 | $3.0M | Reduce -46.0% |
| SLN Silence Therapeutics PLC-ADR | 1.06% | 395,024 | $2.7M | Reduce -17.9% |
| NAMS Newamsterdam Pharma Co. NV | 1.01% | 100,000 | $2.6M | New |
| OCUL Ocular Therapeutix Inc. | 0.64% | 191,456 | $1.6M | New |
| MBX MBX Biosciences Inc. | 0.13% | 18,000 | $332K | New |
Portfolio Sells Q3 2024 → Q4 2024
| PHAT Phathom Pharmaceuticals Inc. | Sold out | 0.00% | −5.65 |
| SLN Silence Therapeutics PLC-ADR | Reduce -17.9% | 1.06% | −2.06 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −2.04 |
| COGT Cogent Biosciences Inc. | Reduce -12.5% | 4.58% | −2.04 |
| PCVX Vaxcyte Inc. | Reduce -0.3% | 6.55% | −1.82 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.94 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -46.0% | 1.18% | −0.82 |
| ITOS Iteos Therapeutics Inc. | Sold out | 0.00% | −0.71 |
| AVBP Arrivent Biopharma Inc. | Sold out | 0.00% | −0.40 |
| LBPH Longboard Pharmaceuticals Inc. | Sold out | 0.00% | −0.38 |
| IRWD Ironwood Pharmaceuticals Inc. | Reduce -27.3% | 1.41% | −0.24 |
| ASND Ascendis Pharma A/S | Reduce -0.7% | 10.73% | +0.04 |
| ARGX Argenx SE - ADR | Reduce -10.7% | 4.76% | +0.47 |
| IRON Disc Medicine Inc. | Reduce -0.3% | 12.65% | +3.67 |
Portfolio Buys Q3 2024 → Q4 2024
| XENE Xenon Pharmaceuticals Inc. | New | 4.95% | +4.95 |
| CTNM Contineum Therapeutics Inc. Class A | Add +641.3% | 3.29% | +2.76 |
| MLTX Moonlake Immunotherapeutics | Add +15.8% | 7.34% | +1.95 |
| SNDX Syndax Pharmaceuticals Inc. | Add +96.9% | 5.12% | +1.66 |
| MRUS Merus NV | Add +78.8% | 3.86% | +1.52 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 1.32% | +1.32 |
| NAMS Newamsterdam Pharma Co. NV | New | 1.01% | +1.01 |
| OCUL Ocular Therapeutix Inc. | New | 0.64% | +0.64 |
| CELC Celcuity Inc. | Add +12.4% | 5.45% | +0.41 |
| CYTK Cytokinetics Inc. | Add +5.2% | 6.42% | +0.17 |
| MBX MBX Biosciences Inc. | New | 0.13% | +0.13 |
| CGON CG Oncology Inc. | Add +14.1% | 6.66% | −0.35 |
| ABVX Abivax SA-ADR | Add +0.8% | 1.87% | −0.80 |
| CRGX Cargo Therapeutics Inc. | Add +0.5% | 5.69% | −0.92 |
| INZY Inozyme Pharma Inc. | Add +0.4% | 1.49% | −1.07 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |